Aislamiento de Haemophilus spp. en exudados uretrales como posible agente etiológico de uretritis aguda: estudio de 38 casos

Magdaleno‐Tapial, Jorge; Valenzuela‐Oñate, Cristian; Weth, M.M. Giacaman-von der; Ferrer-Guillén, Blanca; Martínez‐Doménech, Álvaro; Martínez, Marta García-Legaz; Salvador, José María Ortiz; Subiabre-Ferrer, Daniela; Hernández-Bel, P.

doi:10.1016/j.ad.2018.09.003

Cited by 15 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other bacterial pathogens have been implicated as potential causes of clinical urethritis, either in clustered case series or as sporadic cases such as Haemophilus influenzae and Haemophilus parainfluenzae ( 719 – 723 ). Haemophilus was identified in 12.6% of cases among 413 men (mostly MSM reporting insertive oral sex) ( 724 ), and high rates of azithromycin resistance (39.5%) were identified among Haemophilus urethritis patients ( 725 ). Individual case reports have linked NGU to multiple bacterial species, including Corynebacterium propinquum ( 726 ), Kurthia gibsonii ( 727 ), Corynebacterium glucuronolyticum ( 728 , 729 ), Corynebacterium striatrium ( 730 ), Aerococcus urinae ( 731 ) , and Neisseria elongata ( 732 ).…”

Section: Diseases Characterized By Urethritis and Cervicitismentioning

confidence: 99%

“…M. genitalium is estimated to account for 10%–25% of cases ( 696 , 697 , 701 , 703 , 704 , 706 , 733 , 743 ), and T. vaginalis for 1%–8% of cases depending on population and location ( 703 , 706 , 708 , 710 , 712 ). Other etiologies include different bacteria, such as Haemophilus species ( 724 , 725 ), N. meningitidis ( 713 , 716 ), HSV ( 706 , 717 ), and adenovirus ( 744 ). However, even when extensive testing is performed, no pathogens are identified in approximately half of cases ( 701 , 733 ).…”

Section: Diseases Characterized By Urethritis and Cervicitismentioning

confidence: 99%

See 1 more Smart Citation

Sexually Transmitted Infections Treatment Guidelines, 2021

Workowski¹,

Bachmann²,

Chan³

et al. 2021

MMWR Recomm. Rep.

1,726

2,621

View full text Add to dashboard Cite

These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11-14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs. BOX 1. The Five P's approach for health care providers obtaining sexual histories: partners, practices, protection from sexually transmitted infections, past history of sexually transmitted infections, and pregnancy intention Additional information about external condoms is available at https://www.cdc.gov/condomeffectiveness. Internal CondomsCondoms for internal vaginal use, also known as female condoms, are available worldwide (e.g., the FC2 Female Condom, Reddy condom, Cupid female condom, and Woman's condom) (31,32). Use of internal condoms can provide protection from acquisition and transmission of STIs, although data are limited. Internal condoms are more costly compared with external condoms; however, they offer the advantage of being controlled by the receptive partner as an STI and HIV prevention method, and the newer versions might be acceptable to all persons. Although the internal condom also has been used during receptive anal intercourse, efficacy associated with this practice remains unknown (33). Additional information about the internal condom is available at http://www.ashasexualhealth. org/pdfs/Male_and_Female_Condoms.pdf. Cervical DiaphragmsIn observational studies, diaphragm use has been demonstrated to protect against cervical gonorrhea, chlamydia, and trichomoniasis (34). However, a trial examining the effect of a diaphragm plus lubricant on HIV acquisition among women in Africa reported no additional protective effect when compared with the use of male condoms alone. Likewise, no difference by study arm in the rate of acquisition of chlamydia, gonorrhea, or herpes occurred (35,36). Diaphragms should not be relied on as the sole source of protection against HIV and other STIs.

show abstract